Remed KRX:302550KOSDAQ
리메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days2
Articles tracked11since Sep 11
In Q2 2026, Remed reported revenue of ₩7.4bn, up 32.7% year on year, and operating profit of ₩945m. Remed (리메드) appeared in 1 Korean news article and 2 DART filings over the past seven days. Coverage peaked on Oct 21 with 5 articles. It was most often mentioned alongside 글로벌테크놀로지.
Filing signals Dilution risk Share pledge Screener
Remed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩7.4bn | +32.7% | ₩945m margin 12.8% | ₩272m |
| Q1 2026 | ₩7.2bn | +11.4% | ₩684m margin 9.5% | ₩1.0bn |
| Q4 2025 derived | ₩6.7bn | +3.9% | ₩51m margin 0.8% | −₩204m |
| Q3 2025 | ₩5.8bn | -3.7% | ₩272m margin 4.7% | ₩168m |
| Q2 2025 | ₩5.6bn | -28.4% | ₩25m margin 0.4% | −₩217m |
| Q1 2025 | ₩6.4bn | +21.2% | ₩377m margin 5.9% | ₩218m |
| Q4 2024 derived | ₩6.4bn | +49.4% | −₩250m margin −3.9% | ₩3.1bn |
| Q3 2024 | ₩6.0bn | +44.8% | ₩124m margin 2.1% | ₩3.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Remed top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Remed news Korean headlines
-
LF인베스트먼트, 리메드에 150억 투자… CB 전환 시 2대 주주
1 more on this story · 1 outlets
- LF인베스트먼트, 리메드에 150억 투자… CB 전환 시 2대 주주조선일보 · Oct 15 17:45